Dr. Julia Berian,[/caption]
Julia Berian, MD, MS
ACS Clinical Research Scholar
American College of Surgeons
Chicago, IL 60611
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The US population is rapidly aging and older adults consume a disproportionate share of operations. Older adults experience a high rate of postoperative complications, which can affect quality of life. In this study, function, mobility and living situation are considered together as independent living. The study examined a large surgical database for the occurrence of loss of independence (defined as a decline in function or mobility, or increased care needs in one's living situation) and its relationship to traditional outcomes such as readmission and death after the time of discharge. Patients included in the study were age 65 or older and underwent an inpatient surgical operation. Loss of independence was assessed at the time of discharge. Readmission and death-after-discharge were assessed up to 30 days postoperatively.
Dr. Romy Lauche[/caption]
Romy Lauche, PhD
Chancellor’s Postdoctoral Research Fellow
Australian Research Centre in Complementary and Integrative Medicine (ARCCIM)
Faculty of Health | University of Technology Sydney
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Many people are affected by persistent or recurrent neck pain. So far the only intervention with real benefit is exercise therapy, independent of the type of exercise used. Despite the fact that musculoskeletal disorders including back and neck pain have been found predictive of Tai Chi use, no study to date has investigated its potential in the treatment of chronic non-specific neck pain.
Our study found that 12 weeks of Tai Chi significantly reduced neck pain intensity, and improved quality of life, however no differences were found between Tai Chi and conventional neck exercises. Both interventions were well tolerated, and participants were satisfied with either intervention.
Dr. Shilpa Bhupathiraju[/caption]
Dr. Shilpa Bhupathiraju, PhD
Harvard T.H. Chan
School of Public Health
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We wanted to investigate the association between body mass index (BMI) and mortality across major global regions. In doing so, we wanted to take into account important methodological limitations which plagued prior reports of BMI and mortality. One such limitation is reverse causality where a low body weight is the result of an underlying illness rather than the cause. Another major problem is confounding due to smoking where smokers have lower body weights than non-smokers but have much higher mortality rates.
Therefore, to obtain an unbiased association between BMI and mortality, our primary pre-specified analysis was restricted to never smokers and those who had no existing chronic diseases at the start of the study.
In this group, we found that those with a BMI of 22.5-<25 kg/m2 (considered a healthy weight range) had the lowest mortality risk during the time they were followed. The risk of mortality increased significantly with excess body weight. A BMI of 25-<27.5 kg/m2 (in the overweight range) was associated with a 7% higher risk of premature death; BMI of 27.5-<30 kg/m2 (also in the overweight range) was associated with a 20% higher risk; a BMI of 30.0-<35.0 kg/m2 was associated with a 45% higher risk; a BMI of 35.0-<40.0 kg/m2 was associated with a 94% higher risk; and a BMI of 40.0-<60.0 kg/m2 was associated with a nearly 3-fold risk. In general, we found that the association of excess body weight with mortality was greater in younger than older people and in men than women. Most importantly, the associations were broadly consistent in the major global regions we examined, including Europe, North America, Australia and New Zealand, East Asia, and South Asia.
Brian Meshkin[/caption]
MedicalResearch.com Interview with:
Brian Meshkin
Founder and CEO of Proove Biosciences
Editor’s note: Proove Biosciences, Inc introduced three new evidence-based tests to support better clinical decision-making for difficult-to-treat conditions that are influenced by genetics. These conditions include substance abuse, fibromyalgia and venous thromboembolism. The tests are especially relevant in light of the House of Representatives passing the Comprehensive Addiction Recovery Act (CARA) bill on July 8, 2016 to combat the opioid epidemic.
MedicalResearch.com: Would you update our readers on the significance and implications of the CARA Act? What is the role of genetics in addiction? What is the background for the Proove Addiction™ Profile? How does it aid in addiction management?
Response: CARA is a national piece of legislation to expand access to treatment for drug overdoses and addiction. It also includes some other provisions meant to help address the opioid epidemic. However, there are some serious implications.
First, it does not contain any funding, so it is a bit of a “Potemkin Village”. It is also a bit of a façade because it does not address 50% of the equation. According to the definition of addiction from the American Society of Addiction Medicine (ASAM) and the National Institutes of Drug Abuse (NIDA), about half of substance abuse is due to genetic factors. If you are studying for a test and ignoring half of the material, chances are you are not going to do well on the test. As doctors are confronted with the challenges of objectively assessing pain and knowing which patients are at risk for abuse, they must consider genetics.
The Proove Opioid Risk test combines genetic markers and phenotypic variables into an algorithm to effectively identify patients at low, moderate and high risk for opioid abuse. By knowing this information, a physician can make better decisions about opioids. For low risk patients, a physician can safely prescribe and a patient does not need to fear the opioid prescription they are given – as this is about 50% of the population. For those at moderate risk, a physician can use a greater level of vigilance to monitor those patients with abuse-deterrent formulations, regular urine drug screens, opioid contracts, and other tools to monitor their use. For the small number of patients – less than 10% - that are at high risk, a physician can use alternative forms of pain relief such as interventional procedures or non-opioid analgesics to provide the needed relief to patients.
The Proove Addiction Profile builds on this commitment, by providing genetic data points related to other disorders, such as addictions to alcohol, heroin, cocaine and others. Unfortunately, many patients who screen positive for aberrant behavior, such as having an illicit drug in their urine, are often discharged from care by their doctor. This just gets them lost in the system. By running the Proove Addiction Profile in addition to a urine drug screen, a doctor can better understand the genetic factors associated with the aberrant behavior and refer the troubled patient to an addiction specialist for treatment.
Dr. M. N. V. Ravi Kumar[/caption]
M. N. V. Ravi Kumar PhD
Professor of Pharmaceutical Sciences
Texas A&M Rangel College of Pharmacy
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The use of ligands for receptor-mediated drug delivery offers potential for improving both the safety and efficacy of pharmaceuticals. Research to date, however, has yet to overcome some of the significant challenges of targeted drug delivery, one of which is competitive affinity with endogenous ligands. This competition for the receptor binding site can impair both natural cell processes and uptake of the drug complex across the cell wall.
This article presents a unique, non-competitive active transport strategy for crossing the intestinal barrier. Gambogic acid (GA), as a ligand, was coupled with a polymer called poly(lactic-co--glycolic acid) (PLGA) that in turn can encapsulate drugs forming nanosystems to bind to transferrin receptors within the intestinal wall, which facilitated active gut barrier crossing. The study results show peak plasma concentrations of Cyclosporine A (CsA) in orally dosed rodents at 6 hours with the GA-ladened nanosystems vs 24 hours without GA. Additionally, brain concentrations of CsA are twice as high dosing with PLGA-GA NS compared with PLGA-NS (without GA).
Dr. Y. M. Medina[/caption]
Dr. Yasser Iturria Medina PhD
Post-doctoral fellow
Montreal Neurological Institute
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We used over 200 peripheral molecular biomarkers, five different neuroimaging modalities and cognitive/clinical measurements to detect spatiotemporal abnormalities in subjects with dementia or with mild signs of cognitive deterioration. By means of a mathematical framework, we reordered all the biomarkers/descriptors considered, according to how much they change during the disease process. The results suggested that, contrary as suggested by more traditional clinical analyses, there are multiple early signs of neurodegeneration, at the molecular level and at the brain’s macroscopic and cognitive state. In particular, we observed notable early signs of generalized vascular dysregulation, which may be supporting the vascular hypothesis of Alzheimer’s disease. However, we still need to perform deeper analyzes, in order to clarify the complex causal mechanisms that trigger the disease.
Dr. Kejal Kantarci[/caption]
Kejal Kantarci, M.D. M.S.
Professor of Radiology
Division of Neuroradiology
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: A rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer’s disease risk in women. This study was conducted in newly postmenopausal women who received 17β-Estradiol via a skin patch or conjugated equine estrogen orally or placebo.
Those who received 17β-Estradiol patch had reduced β-amyloid deposits, the plaques found in the brains of people with Alzheimer’s disease, three years after the end of the hormone therapies.
In the study, women with APOE e4 — one form of the most common gene associated with late-onset Alzheimer's disease — who received the 17β-Estradiol patch had lower levels of β-amyloid deposits than those who received placebo.
Ms. Leigh Purvis[/caption]
Leigh Purvis, MPA
Director of Health Services Research
AARP Public Policy Institute
Editors’ note: In conjunction with the AARP’s new investigative piece, 'Supplement Pills That Promise Too Much', Leigh Purvis, Director of the AARP Health Services Research program discussed the issue of the proliferation of supplements, often with labels that make extraordinary health benefit claims.
MedicalResearch.com: How many Americans use nutritional supplements? How big is the business of supplements?
Response: Supplements are very popular in the United States. This is particularly true for older adults. A recent study found that the proportion of older adults using supplements increased from 52 percent in 2005 to 64 percent in 2011, and the share using multiple supplements grew by nearly 50 percent.
According to the National Institutes of Health, American spent an estimated $36.7 billion on dietary supplements in 2014.
Jennifer Polinski[/caption]
Jennifer Polinski, Senior Director
Enterprise Evaluation and Population Health Analytics
CVS Health
Woonsocket, Rhode Island
MedicalResearch.com: What is the background for this study?
Response: Unnecessary and often preventable hospital readmissions are a growing and costly issue. An estimated one in seven patients discharged from a hospital is readmitted within 30 days, and startlingly, readmissions are associated with more than $41 billion in additional health care costs per year. In addition, evidence suggests that approximately 66 percent of hospital readmissions are the result of adverse health events related to medication non-adherence.
Dr. Charbel Moussa[/caption]
Charbel Moussa MD. PhD
Assistant Professor of Neurology
Director- Laboratory for Dementia and Parkinsonism
Clinical Research Director- National Parkinson's Foundation Center for Excellence
Translational Neurotherapeutics Program
Department of Neurology
Georgetown University Medical Center
Washington DC.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We conducted a pilot open label proof-of-concept study to evaluate the safety and tolerability of Nilotinib in participants with advanced Parkinson’s disease (PD) with dementia (PDD) or dementia with Lewy bodies (DLB). Our primary objective is to demonstrate that low oral daily doses of 150mg or 300mg Nilotinib (compared to 600-800mg in cancer) are safe and tolerated.
Our secondary objectives are that Nilotinib will cross the blood brain barier and may inhibit cerebral spinal fluid Abl. Based on preclinical data we also hypothesized that Nilotinib will increase DA levels. Motor and cognitive functions were also measured as exploratory clinical outcomes. Other exploratory outcomes are that Nilotinib may alter PD-related CSF biomarkers DJ-1 and α-synuclein. As most participants in this study had dementia we also explored the effects of Nilotinib on Alzheimer's Disease-related CSF biomarkers, including Aβ40 and Aβ42, total tau and phosphorylated tau (p-tau).
Dr. Jason Busse[/caption]
Jason Busse PhD
Department of Anesthesia
Department of Clinical Epidemiology & Biostatistics
McMaster University
Hamilton, ON
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Persistent pain after breast cancer surgery affects up to 60% of patients. Early identification of those at higher risk could help inform optimal management. We conducted a systematic review and meta-analysis of observational studies to explore factors associated with persistent pain among women who have undergone surgery for breast cancer. We found that development of persistent pain after breast cancer surgery was associated with younger age, radiotherapy, axillary lymph node dissection, greater acute postoperative pain and preoperative pain. Axillary lymph node dissection increases the absolute risk of persistent pain by 21%, and provides the only high yield target for a modifiable risk factor to prevent the development of persistent pain after breast cancer surgery.
Dr. Maksymilian Opolski[/caption]
Dr Maksymilian P. Opolski
Department of Interventional Cardiology and Angiology
Institute of Cardiology
Warsaw, Poland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Valvular heart disease (VHD) that requires surgery is increasingly encountered in industrialized countries. Of particular interest, the presence of concomitant coronary artery disease (CAD) in patients with VHD is related to worse clinical outcomes, and various clinical studies suggested that combined valve and bypass surgery reduces early and late mortality. Consequently, in the majority of such patients, pre-operative evaluation for coronary artery disease (CAD) with invasive coronary angiography is recommended. However, provided that most patients with valvular heart disease are found to have no significant coronary stenoses, coronary computed tomography angiography (coronary CTA) appears as an extremely appealing noninvasive alternative to invasive coronary angiography for exclusion of significant CAD. This is further justified when the risks of angiography outweigh its benefits (e.g. in cases of aortic dissection or aortic vegetation).
Dr-Iliana-Lega[/caption]
Iliana Lega, MD, FRCPC
Assistant Professor
Department of Medicine and a Clinician Scientist
University of Toronto
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Diabetes and cancer share a variety of risk factors that predispose individuals to both conditions. However the exact mechanism of this relationship is unclear. Our study examined differences in cancer diagnosis at different time points around a diagnosis of diabetes. We found two interesting trends.
First, people with diabetes have the highest risk for cancer in the first 3 months following a diagnosis of diabetes.
Second, we found that people with diabetes are also more likely to have had cancer even prior to being diagnosed with diabetes.
Dr. Dejan Nonato[/caption]
Dejan R. Nonato, MD, PhD
Institute of Tropical Pathology and Public Health
School of Medicine
Federal University of Goiás
Goiânia, GO, Brazil
MedicalResearch.com: What is the background for this study?
Response: Human papillomavirus (HPV) and Chlamydia trachomatis (CT) share the same route of sexual transmission and possess similar risk factors, indicating that co-infection may act synergistically in the induction of epithelial cell abnormalities.
Guido Camps[/caption]
Guido Camps, MSc PhD candidate
Wageningen University and Research Centre
The Netherlands
Editor's note: The researcher would like readers to be aware that this work is preliminary and has not yet been published in a peer-reviewed journal.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The background was that we wanted to study gastric distension with actual food. Because using different foods would also change the caloric content, we added water. We wanted to see if we could measure both the stomach and the brain, and what the added distension would feel like to the subjects and what brain effects we could see.
Dr. Matthew James O'Brien[/caption]
Matthew James O'Brien MD
Northwestern University Feinberg School of Medicine
MedicalResearch.com: What is the background for this study?
Response: In October 2015, the United States Preventive Services Task Force (USPSTF) released new diabetes screening guidelines. This government-supported expert group recommended screening asymptomatic adults who are 40-70 years old and overweight or obese for diabetes. Recent population trends show that racial/ethnic minorities develop diabetes at younger ages and lower weights than whites. Therefore, we sought to determine whether these screening criteria may fail to identify racial/ethnic minorities or other high-risk population subgroups. Our study population was 50,515 patients from federally-funded community health centers, which serve large numbers of minorities and socioeconomically disadvantaged individuals.
Dr Fraser W Gibb MBChB PhD FRCP Edin
Consultant Physician / Honorary Clinical Senior Lecturer
Edinburgh Centre for Endocrinology & Diabetes
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We know that diabetic ketoacidosis is associated with a low risk of death in those admitted to hospital but we did not know what the risk of death was in the months and years following discharge from hospital.
We have found that recurrent DKA admissions (more than 5 in a lifetime) are associated with a greater than 1 in 5 risk of death in the following three years compared to a 1 in 20 risk for those with only a single DKA. Recurrent DKA is more common in younger, more socially disadvantaged people.
Dr. Ana I. Vazquez[/caption]
Ana I. Vazquez PhD
Department of Epidemiology and Biostatistics
Michigan State University
East Lansing, Michigan
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Precise predictions of whether a tumor is likely to spread would help clinicians and patients choose the best course of treatment. But current methods fall short of the precision needed. We tested whether breast cancer survival predictions could be improved by profiling primary tumor samples with genomic technologies. We found that predictions based on clinical information, such as cancer stage and subtype, improve when they incorporate comprehensive data on which genes are active in tumor samples compared to non-cancerous tissues from the same patient. This is also true for genome-wide methylation data, which maps the parts of the DNA that carry molecular "tags" that influence gene activation. If developed for use in the clinic, our approach could spare some patients from unneeded chemotherapy.
Dr. Hsin-Jen Chen[/caption]
Hsin-Jen Chen, PhD MS
Assistant Professor
Institute of Public Health
National Yang-Ming University
Taipei City
MedicalResearch.com: What is the background for this study?
Response: The number of eating occasions may affect health. Laboratory experiments have been showing that splitting daily food consumption into more eating occasions could improve metabolic profiles, such as healthier blood glucose and lipids levels. However, such kinds of experiments usually design a highly controlled diet for the participants in the lab. It is questionable whether such metabolic benefits remain in our daily life (namely, no controlled diets) where we can eat at anytime when we want to eat.
Dr. Jun Wang[/caption]
Jun Wang, M.D., Ph.D.
Assistant Professor
Department of Neuroscience and Experimental Therapeutics
Interdisciplinary Program in Neuroscience (TAMU/TAMHSC)
TAMHSC COLLEGE OF MEDICINE
Bryan, TX 77807
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Alcohol use disorder is a big problem for our society and only a limited number of medicine is available. We hope to find more treatment in animal models of alcoholism.
A group of neurons containing dopamine D2 receptors in the brain prevent us from drinking alcohol heavily.
Laura Vater[/caption]
Laura B. Vater, MPH
MD Candidate 2017
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: In the United States, cancer center advertisements are common. Previous research has shown that these ads use emotion-based techniques to influence viewers and omit information about benefits, risks, and costs of cancer treatment. There is a concern that cancer center advertising may increase demand for unnecessary tests and treatments, increase healthcare costs, and provide unrealistic expectations about the benefits of cancer treatment.
In this study, we examined cancer center advertising spending from 2005 to 2014, with particular attention to trends within media (television networks, magazines, newspapers, radio stations, billboards, and the Internet) and by target audience (national versus local).
Dr. Paul Crane[/caption]
Paul K. Crane, MD MPH Professor
Department of Medicine Adjunct Professor
Department of Health Services
University of Washington
MedicalResearch.com: What is the background for this study?
Response: The background is that the most common experience of head injury with loss of consciousness is an apparent recovery. Sometimes this is very fast, sometimes it takes somewhat longer, but typically people return to their prior baseline. Nevertheless there is concern that the head injury may have set in motion processes that would lead to late life neurodegenerative conditions. This is bad enough for someone to deal with but it's made even worse if the head injury isn't even the victim's fault. Previous research has focused especially on Alzheimer's disease. A more limited research has focused on Parkinson's disease.
We used data from three prospective cohort studies that included more than 7,000 people to study the relationship between head injury with loss of consciousness and subsequent risk of Alzheimer's and Parkinson's disease. We collected head injury exposure data at study enrollment, at a time when we administered cognitive tests and knew they did not have dementia, so our exposure data are not biased. Each of these studies also performed brain autopsies on people who died, and we evaluated data from more than 1500 autopsies.
Dr. Suzanne Gilboa[/caption]
Suzanne Meredith Gilboa, PhD
Epidemiologist at the Centers for Disease Control and Prevention’s
National Center on Birth Defects and Developmental Disabilities
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Because of advancements in care, there has been a decline in mortality from congenital heart defects (CHD) over the last several decades. However, there are no current empirical data documenting the number of people living with CHD in the United States (US).
The purpose of this study was to estimate the congenital heart defects prevalence across all age groups in the US for the year 2010. Using prevalence data from Québec, Canada in the year 2010 as a foundation for a mathematical model, we estimated that approximately 2.4 million people (1.4 million adults, 1 million children) were living with CHD in the US in the year 2010. Nearly 300,000 subjects had severe CHD. Overall, there was a slight predominance of females compared to males.